Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …

Background Sharing of equipment used for injecting drug use (IDU) is a substantial cause
of disease burden and a contributor to blood-borne virus transmission. We did a global …

Worldwide, an estimated 130–170 million people have HCV infection. HCV prevalence is
highest in Egypt at >10% of the general population and China has the most people with HCV (…

Background Since the release of the first global hepatitis elimination targets in 2016, and until
the COVID-19 pandemic started in early 2020, many countries and territories were making …

Aims This review provides an up‐to‐date curated source of information on alcohol, tobacco
and illicit drug use and their associated mortality and burden of disease. Limitations in the …

Importance Mortality among people with opioid dependence is higher than that of the general
population. Opioid agonist treatment (OAT) is an effective treatment for opioid dependence…

Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …

We summarise the evidence for medicinal uses of opioids, harms related to the extramedical
use of, and dependence on, these drugs, and a wide range of interventions used to …

Although 20%‐40% of persons with acute hepatitis C virus (HCV) infection demonstrate
spontaneous clearance, the time course and factors associated with clearance remain poorly …

Background & Aims The risk of hepatocellular carcinoma (HCC) occurrence or recurrence
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …